Merck & Co Takes Up Astex/Taiho SHP2 Program
Indicates Growing Pharma Interest
Merck & Co joins ranks of big pharma firms pursuing the SHP2 area of oncology as it picks up global rights to a portfolio of inhibitors originating from two affiliates of Japan's Otsuka Pharmaceutical.
